Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Silo Pharma Inc (NQ: SILO )

1.100 -0.130 (-10.57%)
Streaming Delayed Price Updated: 3:59 PM EST, Nov 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Silo Pharma Inc

< Previous 1 2 3 4 5 6 Next >
BioMedNewsBreaks — Silo Pharma Inc. (NASDAQ: SILO) Reports Promising Results from Testing of Ketamine-Loaded Implant for Chronic Pain Relief
Via Investor Brand Network
Silo Pharma Reports Positive Results in Sterilization and Dissolution Testing of SP-26 Ketamine Implant
From Silo Pharma, Inc.
Via GlobeNewswire
BioMedNewsBreaks — Silo Pharma Inc. (NASDAQ: SILO) Reports on FDA Pre-IND Meeting to Advance Development of Lead Program
Via Investor Brand Network
Exposures Product Safety
Silo Pharma Announces Completion of FDA Pre-IND Meeting to Advance Development of SPC-15 for Treatment of PTSD
From Silo Pharma, Inc.
Via GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO), Sever Pharma Expand Existing Agreement to Include Extrusion of Novel Ketamine Implant Therapeutic
Via Investor Brand Network
Silo Pharma Expands Development Agreement with Sever Pharma for Novel Ketamine Implant Therapeutic
From Silo Pharma, Inc.
Via GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Enters Agreement to Launch New Study of SPU-16 Homing Peptide for Multiple Sclerosis
Via Investor Brand Network
Silo Pharma Announces Partnership with Global CRO for Central Nervous System Homing Peptide
From Silo Pharma, Inc.
Via GlobeNewswire
BioMedNewsBreaks — Silo Pharma Inc. (NASDAQ: SILO) to Participate in Upcoming H.C. Wainwright Annual Global Investment Conference
Via Investor Brand Network
Silo Pharma to Present at H.C. Wainwright Annual Global Investment Conference
From Silo Pharma, Inc.
Via GlobeNewswire
Silo Pharma Announces Closing of $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
From Silo Pharma, Inc.
Via GlobeNewswire
BioMedNewsBreaks — Silo Pharma Inc. (NASDAQ: SILO) Enters into $2.1M Registered Direct Offering
Via Investor Brand Network
Silo Pharma Announces $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
From Silo Pharma, Inc.
Via GlobeNewswire
BioMedNewsBreaks — Silo Pharma Inc. (NASDAQ: SILO) Enters Device and CMC Development Master Plan to Support IND-Enabling Study of SPC-15
Via Investor Brand Network
Silo Pharma and Resyca BV Partner on Device and CMC Development for Intranasal PTSD Drug SPC-15
From Silo Pharma, Inc.
Via GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Exclusive Global License to Develop, Manufacture, Commercialize Alzheimer Drug
Via Investor Brand Network
Silo Pharma Secures Exclusive Global License for Alzheimer's Therapeutic
From Silo Pharma, Inc.
Via GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Enters License Agreement with Columbia University for Lead Candidate Targeting PTSD, Stress-Induced Anxiety Disorders
Via Investor Brand Network
Exposures Product Safety
Silo Pharma Announces Exclusive, Global License for Lead Candidate SPC-15 Targeting PTSD and Stress-Induced Anxiety Disorders
From Silo Pharma, Inc.
Via GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Collaborates with CRO Partner to Advance SPC-15 for PTSD
Via Investor Brand Network
Silo Pharma Partners with AmplifyBio to Advance SPC-15 for PTSD and Anxiety
From Silo Pharma, Inc.
Via GlobeNewswire
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Closes on $2M Registered Direct Offering, Provides Update on SP-26 Ketamine Implant Therapeutic
Via Investor Brand Network
Silo Pharma Announces Successful Production of its SP-26 Ketamine Implant for Fibromyalgia
From Silo Pharma, Inc.
Via GlobeNewswire
Silo Pharma Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
From Silo Pharma, Inc.
Via GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Enters Registered Direct Offering Estimated to Reach $2M
Via Investor Brand Network
Silo Pharma Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
From Silo Pharma, Inc.
Via GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Pre-IND Submission for Proprietary Treatment for PTSD, Anxiety
Via Investor Brand Network
Exposures Product Safety
Silo Pharma Submits Pre-Investigational New Drug Application to FDA for SPC-15 as a Treatment for PTSD and Anxiety
From Silo Pharma, Inc.
Via GlobeNewswire
Silo Pharma’s (NASDAQ: SILO) Promising Developments and Key Insights for Traders and Investors
Via AB Newswire
Exposures Product Safety
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Shares ‘Significant Development’ in Depression Study Showing Potential to Extend Remission Period, Prevent Relapse
Via Investor Brand Network
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

© Copyright 2015, Penticton Herald, Penticton, BC. Powered by BLOX Content Management System from TownNews.com.